DK3560937T3 - Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed - Google Patents

Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed Download PDF

Info

Publication number
DK3560937T3
DK3560937T3 DK19179758.8T DK19179758T DK3560937T3 DK 3560937 T3 DK3560937 T3 DK 3560937T3 DK 19179758 T DK19179758 T DK 19179758T DK 3560937 T3 DK3560937 T3 DK 3560937T3
Authority
DK
Denmark
Prior art keywords
methods
making
imaging agents
labeled psma
targeting imaging
Prior art date
Application number
DK19179758.8T
Other languages
English (en)
Inventor
Clifford Berkman
Svetlana A Stekhova
Original Assignee
Cancer Targeted Tech Llc
Univ Washington State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc, Univ Washington State filed Critical Cancer Targeted Tech Llc
Application granted granted Critical
Publication of DK3560937T3 publication Critical patent/DK3560937T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19179758.8T 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed DK3560937T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798108P 2013-03-15 2013-03-15
EP14721640.2A EP2970345B1 (en) 2013-03-15 2014-03-14 18f-labeled psma-targeted pet imaging agents

Publications (1)

Publication Number Publication Date
DK3560937T3 true DK3560937T3 (da) 2023-02-13

Family

ID=50639969

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19179758.8T DK3560937T3 (da) 2013-03-15 2014-03-14 Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed
DK14721640.2T DK2970345T3 (da) 2013-03-15 2014-03-14 18f-mærkede psma-targeterede pet-kontrastmidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14721640.2T DK2970345T3 (da) 2013-03-15 2014-03-14 18f-mærkede psma-targeterede pet-kontrastmidler

Country Status (17)

Country Link
US (3) US11554183B2 (da)
EP (3) EP2970345B1 (da)
CN (2) CN105308056B (da)
AU (2) AU2014228233B2 (da)
CA (1) CA2903131C (da)
DK (2) DK3560937T3 (da)
ES (2) ES2743433T3 (da)
FI (1) FI3560937T3 (da)
HR (2) HRP20191482T1 (da)
HU (2) HUE061402T2 (da)
LT (2) LT2970345T (da)
PL (2) PL2970345T3 (da)
PT (2) PT2970345T (da)
RS (1) RS64011B1 (da)
SI (2) SI2970345T1 (da)
SM (1) SMT202300035T1 (da)
WO (1) WO2014143736A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078166B2 (en) 2015-08-13 2021-08-03 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
MX392700B (es) * 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
EP3600024B1 (en) 2017-03-22 2024-10-23 SafeOp Surgical, Inc. Medical system and method for detecting changes in electrophysiological evoked potentials
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CA3215723A1 (en) 2021-04-02 2022-10-06 Advanced Accelerator Applications Diagnostic methods of prostate cancer
EP4761763A1 (en) 2023-08-14 2026-06-24 Cancer Targeted Technology LLC Psma binding ligand-linker conjugates and methods for use thereof
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1999136T3 (pl) 2006-03-14 2013-03-29 Cancer Targeted Tech Llc Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
BRPI0716554A2 (pt) * 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
ES2634894T3 (es) * 2008-08-01 2017-09-29 The Johns Hopkins University Agentes de unión a PSMA y usos de los mismos
WO2012064914A2 (en) * 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma
PL2721039T3 (pl) * 2011-06-15 2018-06-29 Cancer Targeted Technology Llc Chelatowane inhibitory PSMA
CN102757296B (zh) * 2012-04-10 2014-11-19 中国科学院上海应用物理研究所 一种对化合物进行[18f]标记的方法
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors

Also Published As

Publication number Publication date
EP2970345A1 (en) 2016-01-20
ES2743433T3 (es) 2020-02-19
EP4180438A1 (en) 2023-05-17
PL2970345T3 (pl) 2019-12-31
US20250375542A1 (en) 2025-12-11
AU2019203610A1 (en) 2019-06-13
SI3560937T1 (sl) 2023-04-28
ES2937955T3 (es) 2023-04-03
CN108558939B (zh) 2021-08-24
LT2970345T (lt) 2019-09-25
LT3560937T (lt) 2023-03-27
EP3560937A1 (en) 2019-10-30
HUE061402T2 (hu) 2023-06-28
CA2903131C (en) 2021-11-23
PL3560937T3 (pl) 2023-03-27
US20230144322A1 (en) 2023-05-11
HRP20191482T1 (hr) 2019-11-15
AU2014228233A1 (en) 2015-09-17
CA2903131A1 (en) 2014-09-18
US11554183B2 (en) 2023-01-17
AU2014228233B2 (en) 2019-02-28
CN108558939A (zh) 2018-09-21
SMT202300035T1 (it) 2023-05-12
WO2014143736A1 (en) 2014-09-18
CN105308056B (zh) 2018-03-20
US20160030605A1 (en) 2016-02-04
EP2970345B1 (en) 2019-06-19
RS64011B1 (sr) 2023-03-31
EP3560937B1 (en) 2022-12-28
SI2970345T1 (sl) 2019-11-29
DK2970345T3 (da) 2019-08-26
PT2970345T (pt) 2019-09-06
AU2019203610B2 (en) 2021-02-04
HRP20230109T1 (hr) 2023-04-28
PT3560937T (pt) 2023-02-13
HUE046194T2 (hu) 2020-02-28
CN105308056A (zh) 2016-02-03
FI3560937T3 (fi) 2023-02-28

Similar Documents

Publication Publication Date Title
DK3090068T3 (da) Fremgangsmåde og kit til ikke-invasiv detektering af egfr-genmutationer
DK3041926T3 (da) Indretning til in-vitro-modellering af in-vivo-væv af organer
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
DK3988168T3 (da) Enheder og metoder til ultralydskosmetik med flere fokus
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK2742857T3 (da) Integration af intra-oral afbildning og volumetrisk afbildning
DK3363805T3 (da) Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner
PT3295951T (pt) Anticorpos anti-pvrig e métodos de utilização
DK3736292T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3055803T3 (da) Sporing og analyse af kliniske resultater
DK3350341T3 (da) Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis
EP2967552A4 (en) FABRICATING BONE ANCHOR
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
EP3084419C0 (en) ADVANCED ULTRASONIC INSPECTION
HUE050430T2 (hu) Fekális mikrobióta mintavételezési eljárás
DK3347016T3 (da) Diagnosticering og behandling af angstlidelse
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3117030T3 (da) Diagnosticering af sepsis
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3467111T3 (da) LNCRNAS til terapi og diagnose af hjertehypertrofi
DK3123381T3 (da) Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf